Figure 2
Anti-CD137 agonistic mAb has potent antilymphoma activity in vivo. BALB/c mice were inoculated subcutaneously with 5 × 106 A20 tumor cells. Mice received either no treatment or 2 intraperitoneal injections of mAb anti-OX40 mAb, anti-CTLA4 mAb, anti-GITR mAb, or anti-CD137 mAb at days 5 and 10 after tumor inoculation as described in “Tumor transplantation and immunotherapy.” Mice (10 per group) were then monitored for tumor growth (A, mean ± SEM) and overall survival (B).
